Inflammation and Age-related Macular Degeneration
By:  Jayakrishna Ambati, MD
New research expands understanding of how inflammation and the complement system contribute to AMD disease progression

Bevacizumab vs Triamcinolone for Diabetic Macular Edema
By:  Mark Gillies, PhD, FRANZCO
Look before you leap

Combination Treatments for CNV in AMD
By:  Peter K. Kaiser, M.D.
Early reports show promising results with several combinations of therapies

Comorbid Conditions in Vitreoretinal Surgery
By:  Shawn Wilker, MD; Julia A. Haller, MD; Diana V. Do, MD
Awareness of existing health conditions improves surgical results

OCT Imaging: Advances Over the Past 5 Years and Beyond
By:  Henry Alexander Leder, MD; Scott W. Cousins, MD
Optical coherence technology has come a long way, and it continues to move forward

Treatments on the Horizon for AMD Highlighted at RPS
Research is going beyond anti-VEGF to novel approaches to wet and dry AMD

PrONTO Boosts Hope for Variable Dosing of Ranibizumab
OCT-guided therapy may reduce frequency of injections for some patients

What Lies Beyond VEGF in the Treatment of PDR and DME?
Highlights from the Annual Charles L. Schepens Lecture

IVTA to the Rescue?
Triamcinolone tested for ranibizumab failure

VEGF Trap Phase 2 Study Shows Efficacy, Safety
CLEAR-IT 2 Primary Endpoint Results Disclosed

Retisert Reimplantation Appears Safe and Effective
Similar control of inflammation seen, as from first procedure

Study Seeks to Prove Safety and Efficacy of 2.5-mg Bevacizumab
Higher dosing may offer trend toward improved VA, less frequent injections

Sterile Endophthalmitis After Intravitreal Triamcinolone
Inflammation following injections is not always a result of preservatives

Is Scleral Buckling on the Endangered Species List?
Retinal specialist argues that PPV is making this procedure obsolete

Glycemic Control a Possible Factor in DR Progression
A trend in lower rates in diabetic retinopathy may be indicative of better diabetes management

Triple Therapy for Wet AMD Shows Impressive Results
Dynamic disease requires complex approach

Proliferative Vitreoretinopathy
By:  Marc J. Spirn, MD; Carl D. Regillo, M.D.

Retinal and Uveal Drug Toxicity
By:  Esther Kim, BA; Howard F Fine, MD, MHSc; Michael D. Ober, MD

Point/Counterpoint
By:  John S. Pollack, MD
23-g vs. 25-g vitrectomy surgery

Why (and When) I Prefer 25-g Vitrectomy
By:  Carl C. Awh, M.D.

Transient Monocular Visual Loss Due to Primary Vasospasm: A Case Study
By:  Jacqueline M.S. Winterkorn, MD, PhD

A Pixel Is Worth a Thousand Words
By:  David Heiden, MD
The Development of Ophthalmic Imaging and OCT

Retina Ambulatory Surgery Center Myths Debunked
By:  Pravin U. Dugel, MD; Michael A. Romansky, J.D. ; Steve Charles, MD, FACS, FICS

Retinal Regeneration Study Shows Encouraging Early Results
By:  Rochelle Nataloni, Contributing Editor
Phase 1 trial demonstrates therapeutic benefit without damage to the targeted structure

Upfront
By:  Jason S. Slakter, M.D.
From the editor-in-chief

Subspecialty News
Genentech defends its position on Avastin and compounding pharmacies and more

Face Off
By:  Abdhish R. Bhavsar, M.D.
NSAIDs for post-vitrectomy and scleral buckle cases

Coding Q&A
By:  Riva Lee Asbell
Update on extended ophthalmoscopy

Clinical Trial Spotlight
By:  Andrew E. Mathis, PhD, Medical Editor
The CATT trial

Upfront
By:  Jason S. Slakter, M.D.
From the editor-in-chief

Guest Editorial
By:  Charles C. Barr, MD
Reflections on a Unique Group of Physicians

Subspecialty News
By:  Jerry Helzner, Senior Editor
OPKO’s SiRNA drug for AMD shows promise and more

Coding Q&A
By:  Riva Lee Asbell
CPT codes for retinal procedures are changed for 2008

Clinical Trial Update